CH_2, group is replaced with O, or with NH, or with S, or with SO_2 or a $-CH_3$ group at the terminus of the chain or on a branch is replaced with OH or with NH_2) wherein said chain is optionally substituted by one or more groups (for example 1 to 3, such as 2 groups) independently selected from oxo, halogen, an aryl group, a heteroaryl group, a carbocyclyl group or a heterocyclyl group,

each aryl, heteroaryl, carbocyclyl or heterocyclyl group bearing:
0 to 3 substituents selected from halogen, -hydroxyl, -C_{1-6} alkyl, -C_{1-6} alkoxy, -C_{2-3} alkoxyOC_{1-3} alkyl, -C_{2-3} alkylOC_{1-3} alkyl, -C_{1-3} hydroxyalkyl, -C_{1-6} haloalkyl, amino, -C_{1-4} mono or -C_{2-8} di-alkyl amino, -C_{1-4} mono or -C_{2-8} di-acyl amino, -C_{0-6} alkyl$S(O)_pC_{1-6}$ alkyl, -C_{0-6} alkyl$S(O)_pNR^6R^7$, -C_{0-6} alkylNR^8C_{0-6}alkyl$S(O)_pC_{1-6}$ alkyl, -C_{0-6} alkyl$C(O)OC_{0-6}$ alkyl, -NR^8C_{0-6} alkyl$C(O)NR^6R^7$ -NR^8C_{0-6} alkyl$C(O)C_{0-6}$ alkyl, -C_{0-6} alkyl$C(O)NR^6R^7$, and -C_{0-6} alkyl$C(O)C_{1-6}$ alkyl; and/or one aryl, heterocyclyl or carbocyclyl;

X is C_{6-10} aryl or a C_{5-9} heteroaryl each substituted by R^{2a} and by R^{2b}
wherein R^{2a} is selected from hydrogen, -C_{1-3} alkyl, halo, hydroxyl, cyano, -C_{1-3} haloalkyl, -C_{1-3} alkoxy, -C_{2-3} alkoxyOC_{1-3} alkyl, -C_{2-3} alkylOC_{1-3} alkyl, -C_{1-3} hydroxyalkyl, -C_{0-6} alkyl$S(O)_qC_{1-3}$ alkyl, -C_{0-6} alkyl$S(O)_pNR^6R^7$, -C_{0-6} alkylNR^8C_{0-6}alkyl$S(O)_pC_{1-6}$ alkyl, -C_{0-6} alkyl$C(O)OH$, -C_{0-6} alkyl$C(O)OC_{1-6}$ alkyl, -NR^8C_{0-6} alkyl$C(O)NR^6R^7$, -NR^8C_{0-6} alkyl$C(O)C_{1-6}$ alkyl, -C_{0-6} alkyl$C(O)NR^6R^7$ and -C_{0-6} alkyl$C(O)C_{1-6}$ alkyl; and
R^{2b} is selected from hydrogen, C_{1-3} alkyl, halo, hydroxyl, cyano, -C_{1-3} haloalkyl, -C_{1-3} alkoxy, and -C_{0-6} alkyl$S(O)_qC_{1-3}$ alkyl;

R^{3a} is hydroxyl;
R^{3b} is selected from hydrogen, hydroxyl, halo, cyano, -C_{1-3} haloalkyl, -C_{1-3} hydroxyalkyl, -C_{1-3} alkoxy, and -$S(O)_qC_{1-3}$ alkyl;
R^4 is hydrogen or -C_{1-3} alkyl;
R^5 is hydrogen or -C_{1-3} alkyl;
R^6 is hydrogen or -C_{1-6} alkyl;
R^7 is hydrogen or -C_{1-6} alkyl;
R^8 is hydrogen or -C_{1-6} alkyl;
p is 0 or an integer 1 or 2;
q is 0 or an integer 1 or 2
or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof;
provided that the compound of formula (I) is not 6-(2-((4-amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*,*N*-bis(2-methoxyethyl)hex-5-ynamide.
The disclaimed compound is claimed in WO2012/052753.


In one embodiment R^1 is H, a saturated or unsaturated, branched or unbranched C_{1-12} alkyl chain, wherein optionally one or more carbons (for example 1, 2 or 3 carbons, suitably 1

or 2, in particular 1) is/are replaced by a heteroatom selected from O, N, $S(O)_p$, (for example a CH_2, group is replaced with O, or with NH, or with S, or with SO_2 or a $-CH_3$ group at the terminus of the chain or on a branch is replaced with OH or with NH_2)

X is C_{6-10} aryl or a C_{5-9} heteroaryl each substituted by R^{2a} and optionally by R^{2b}
wherein R^{2a} is hydrogen, -C_{1-3} alkyl, halo, hydroxyl, cyano, -C_{1-3} haloalkyl, -C_{1-3} alkoxy, -C_{2-3} alkoxyOC_{1-3} alkyl, -C_{1-3} hydroxyalkyl, -C_{0-6} alkyl$S(O)_qC_{1-3}$ alkyl, -C_{0-6} alkyl$S(O)_pNR^6R^7$, -C_{0-6} alkylNR^8C_{0-6}alkyl$S(O)_pC_{1-6}$ alkyl, -C_{0-6} alkyl$C(O)OH$, -C_{0-6} alkyl$C(O)OC_{1-6}$ alkyl, -NC_{0-6} alkyl$C(O)NR^6R^7$, -NR^8C_{0-6} alkyl$C(O)C_{1-6}$ alkyl, -C_{0-6} alkyl$C(O)NR^6R^7$ and -C_{0-6} alkyl$C(O)C_{1-6}$ alkyl; and
R^{2b} is hydrogen, C_{1-3} alkyl, halo, cyano, -C_{1-3} haloalkyl, -C_{1-3} alkoxy, -C_{0-6} alkyl$S(O)_qC_{1-3}$ alkyl;

R^{3a} is hydroxyl;
R^{3b} is hydrogen, hydroxyl, halo, cyano, -C_{1-3} haloalkyl, -C_{1-3} hydroxyalkyl, -C_{1-3} alkoxy, -$S(O)_qC_{1-3}$ alkyl;
R^4 is hydrogen or -C_{1-3} alkyl;
R^5 is hydrogen or -C_{1-3} alkyl;
R^6 is hydrogen or -C_{1-6} alkyl;
R^7 is hydrogen or -C_{1-6} alkyl;
R^8 is hydrogen or -C_{1-6} alkyl;
p is 0 or an integer 1 or 2;
q is 0 or an integer 1 or 2
or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof.

In one embodiment the present disclosure provides a compound of formula (**IA'**):



(IA')

R^1 is H, a saturated or unsaturated, branched or unbranched C_{1-15} alkyl chain, wherein optionally one or more carbons (for example 1, 2 or 3 carbons, suitably 1 or 2, in particular 1) is/are replaced by a heteroatom selected from O, N, $S(O)_p$, (for example a CH_2, group is replaced with O, or with NH, or with S, or with SO_2 or a $-CH_3$ group at the terminus of the chain or on a branch is replaced with OH or with NH_2) wherein said chain is optionally substituted by one or more groups (for example 1 to 3, such as 2

groups) independently selected from oxo, halogen, an aryl group, a heteroaryl group, a carbocyclyl group or a heterocyclyl group,

each aryl, heteroaryl, carbocyclyl or heterocyclyl group bearing:

0 to 3 substituents selected from halogen, -hydroxyl, -C_{1-6} alkyl, -C_{1-6} alkoxy, -C_{2-3} alkoxyOC_{1-3} alkyl, -C_{2-3} alkylOC_{1-3} alkyl, -C_{1-3} hydroxyalkyl, -C_{1-6} haloalkyl, amino, -C_{1-4} mono or -C_{2-8} di-alkyl amino, -C_{1-4} mono or -C_{2-8} di-acyl amino, -C_{0-6} alkyl$S(O)_pC_{1-6}$ alkyl, -C_{0-6} alkyl$S(O)_pNR^6R^7$, -C_{0-6} alkylNR^8C_{0-6}alkyl$S(O)_pC_{1-6}$ alkyl, -C_{0-6} alkyl$C(O)OC_{0-6}$ alkyl, -NR^8C_{0-6} alkyl$C(O)NR^6R^7$ -NR^8C_{0-6} alkyl$C(O)C_{0-6}$ alkyl, -C_{0-6} alkyl$C(O)NR^6R^7$, and -C_{0-6} alkyl$C(O)C_{1-6}$ alkyl; and/or one aryl, heterocyclyl or carbocyclyl;

R^{2a} is hydrogen, -C_{1-3} alkyl, halo, hydroxyl, cyano, -C_{1-3} haloalkyl, -C_{1-3} alkoxy, -C_{2-3} alkoxyOC_{1-3} alkyl, -C_{1-3} hydroxyalkyl, -C_{0-6} alkyl$S(O)_qC_{1-3}$ alkyl, -C_{0-6} alkyl$S(O)_pNR^6R^7$, -C_{0-6} alkylNR^8C_{0-6}alkyl$S(O)_pC_{1-6}$ alkyl, -C_{0-6} alkyl$C(O)OH$, -C_{0-6} alkyl$C(O)OC_{1-6}$ alkyl, -NC_{0-6} alkyl$C(O)NR^6R^7$, -NR^8C_{0-6} alkyl$C(O)C_{1-6}$ alkyl, -C_{0-6} alkyl$C(O)NR^6R^7$ and -C_{0-6} alkyl$C(O)C_{1-6}$ alkyl;

R^{2b} is hydrogen, C_{1-3} alkyl, halo, cyano, C_{1-3} haloalkyl, C_{1-3} alkoxy, C_{0-6} alkyl$S(O)_qC_{1-3}$ alkyl;

R^{3a} is hydroxyl;

R^{3b} is hydrogen, hydroxyl, halo, cyano, C_{1-3} haloalkyl, C_{1-3} hydroxyalkyl, C_{1-3} alkoxy, $S(O)_qC_{1-3}$ alkyl;

R^4 is hydrogen or -C_{1-3} alkyl;

R^5 is hydrogen or -C_{1-3} alkyl;

R^6 is hydrogen or -C_{1-6} alkyl;

R^7 is hydrogen or -C_{1-6} alkyl;


R^8 is hydrogen or -C_{1-6} alkyl;

p is 0 or an integer 1 or 2;

q is 0 or an integer 1 or 2

or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof.

In one embodiment the present disclosure provides a compound of formula (**IA**):



(IA)

R^1 is H, a saturated or unsaturated, branched or unbranched C_{1-15} alkyl chain (such as a C_{1-12} alkyl chain or a C_{1-10} alkyl chain), wherein optionally one or more carbons (for example 1, 2 or 3 carbons, suitably 1 or 2, in particular 1) is/are replaced by a heteroatom selected from O, N, $S(O)_p$, (for example a CH_2, group is replaced with O, or with NH, or with S, or with SO_2 or a $-CH_3$ group at the terminus of the chain or on a branch is replaced with OH or with NH_2) wherein said chain is optionally substituted by one or more groups independently selected from oxo, halogen, an aryl group, a heteroaryl group, a carbocyclyl group or a heterocyclyl group

each aryl, heteroaryl, carbocyclyl or heterocyclyl group bearing:

0 to 3 substituents selected from halogen, $-C_{1-6}$ alkyl, $-C_{1-6}$ alkoxy, $-C_{2-3}$ alkoxyOC_{1-3} alkyl, $-C_{1-6}$ haloalkyl, amino, $-C_{1-4}$ mono or $-C_{2-8}$ di-alkyl amino, $-C_{1-4}$ mono or $-C_{2-8}$ di-acyl amino, $-C_{0-6}$ alkyl$S(O)_pC_{1-6}$ alkyl, $-C_{0-6}$ alkyl$S(O)_pNR^6R^7$, $-C_{0-6}$ alkylNR^8C_{0-6}alkyl$S(O)_pC_{1-6}$ alkyl, $-C_{0-6}$ alkyl$C(O)OC_{0-6}$ alkyl, $-NC_{0-6}$ alkyl$C(O)NR^6R^7$ $-NC_{0-6}$ alkyl$C(O)C_{0-6}$ alkyl, $-C_{0-6}$ alkyl$C(O)NR^6R^7$, and $-C_{0-6}$ alkyl$C(O)C_{1-6}$ alkyl; and/or one aryl, heterocyclyl or carbocyclyl;

R^{2a} is hydrogen, $-C_{1-3}$ alkyl, halo, hydroxyl, cyano, $-C_{1-3}$ haloalkyl, $-C_{1-3}$ alkoxy, $-C_{2-3}$ alkoxyOC_{1-3} alkyl, $-C_{1-3}$ hydroxyalkyl, $-C_{0-6}$ alkyl$S(O)_qC_{1-3}$ alkyl, $-C_{0-6}$ alkyl$S(O)_pNR^6R^7$, $-C_{0-6}$ alkylNR^8C_{0-6}alkyl$S(O)_pC_{1-6}$ alkyl, $-C_{0-6}$ alkyl$C(O)OH$, $-C_{0-6}$ alkyl$C(O)OC_{1-6}$ alkyl, $-NC_{0-6}$ alkyl$C(O)NR^6R^7$, $-NR^8C_{0-6}$ alkyl$C(O)C_{1-6}$ alkyl, $-C_{0-6}$ alkyl$C(O)NR^6R^7$ and $-C_{0-6}$ alkyl$C(O)C_{1-6}$ alkyl;

R^{2b} is hydrogen, C_{1-3} alkyl, halo, cyano, C_{1-3} haloalkyl, C_{1-3} alkoxy, C_{0-6} alkyl$S(O)_qC_{1-3}$ alkyl;

R^{3a} is hydroxyl;

R^{3b} is hydrogen, hydroxyl, halo, cyano, C_{1-3} haloalkyl, C_{1-3} hydroxyalkyl, C_{1-3} alkoxy, $S(O)_qC_{1-3}$ alkyl;

R^4 is hydrogen or $-C_{1-3}$ alkyl;

R^5 is hydrogen or $-C_{1-3}$ alkyl;

R^6 is hydrogen or $-C_{1-6}$ alkyl;

R^7 is hydrogen or $-C_{1-6}$ alkyl;


R^8 is hydrogen or $-C_{1-6}$ alkyl;

p is 0 or an integer 1 or 2;

q is 0 or an integer 1 or 2

or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof.

According to the invention, there is provided a compound of formula (**IB'**):



IB'

wherein

R^1 is H, a saturated or unsaturated, branched or unbranched C_{1-15} alkyl chain, wherein optionally one or more carbons (for example 1, 2 or 3 carbons, suitably 1 or 2, in particular 1) is/are replaced by a heteroatom selected from O, N, $S(O)_p$, (for example a CH_2, group is replaced with O, or with NH, or with S, or with SO_2 or a $-CH_3$ group at the terminus of the chain or on a branch is replaced with OH or with NH_2) wherein said chain is optionally substituted by one or more groups (for example 1 to 3, such as 2 groups) independently selected from oxo, halogen, an aryl group, a heteroaryl group, a carbocyclyl group or a heterocyclyl group,

each aryl, heteroaryl, carbocyclyl or heterocyclyl group bearing:

0 to 3 substituents selected from halogen, -hydroxyl, $-C_{1-6}$ alkyl, $-C_{1-6}$ alkoxy, $-C_{2-3}$ alkoxyOC_{1-3} alkyl, $-C_{2-3}$ alkylOC_{1-3} alkyl, $-C_{1-3}$ hydroxyalkyl, $-C_{1-6}$ haloalkyl, amino, $-C_{1-4}$ mono or $-C_{2-8}$ di-alkyl amino, $-C_{1-4}$ mono or $-C_{2-8}$ di-acyl amino, $-C_{0-6}$ alkyl$S(O)_pC_{1-6}$ alkyl, $-C_{0-6}$ alkyl$S(O)_pNR^6R^7$, $-C_{0-6}$ alkylNR^8C_{0-6}alkyl$S(O)_pC_{1-6}$ alkyl, $-C_{0-6}$ alkyl$C(O)OC_{0-6}$ alkyl, $-NR^8C_{0-6}$ alkyl$C(O)NR^6R^7$ $-NR^8C_{0-6}$ alkyl$C(O)C_{0-6}$ alkyl, $-C_{0-6}$ alkyl$C(O)NR^6R^7$, and $-C_{0-6}$ alkyl$C(O)C_{1-6}$ alkyl; and/or one aryl, heterocyclyl or carbocyclyl;

R^{2a} is hydrogen, $-C_{1-3}$ alkyl, halo, hydroxyl, cyano, $-C_{1-3}$ haloalkyl, $-C_{1-3}$ alkoxy, $-C_{2-3}$ alkoxyOC_{1-3} alkyl, $-C_{1-3}$ hydroxyalkyl, $-C_{0-6}$ alkyl$S(O)_qC_{1-3}$ alkyl, $-C_{0-6}$ alkyl$S(O)_pNR^6R^7$, $-C_{0-6}$ alkylNR^8C_{0-6}alkyl$S(O)_pC_{1-6}$ alkyl, $-C_{0-6}$ alkyl$C(O)OH$, $-C_{0-6}$ alkyl$C(O)OC_{1-6}$ alkyl, $-NC_{0-6}$ alkyl$C(O)NR^6R^7$, $-NR^8C_{0-6}$ alkyl$C(O)C_{1-6}$ alkyl, $-C_{0-6}$ alkyl$C(O)NR^6R^7$ and $-C_{0-6}$ alkyl$C(O)C_{1-6}$ alkyl;

R^{3a} is hydroxyl;

R^4 is hydrogen or $-C_{1-3}$ alkyl;

R^5 is hydrogen or $-C_{1-3}$ alkyl;


R^6 is hydrogen or $-C_{1-6}$ alkyl;

R^7 is hydrogen or $-C_{1-6}$ alkyl;

R^8 is hydrogen or $-C_{1-6}$ alkyl;

R^5 is hydrogen or -C_{1-3} alkyl;
R^6 is hydrogen or -C_{1-6} alkyl;
R^7 is hydrogen or -C_{1-6} alkyl;
R^8 is hydrogen or -C_{1-6} alkyl;
p is 0 or an integer 1 or 2;
q is 0 or an integer 1 or 2
or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof.


In one embodiment there is provided a compound of formula (**IC**):



(IC)

wherein R^1, R^{3a}, R^{3b}, R^4 and R^5 are as defined above for compounds of formula (**I**).

In one embodiment there is provided a compound of formula (**ID**):



(ID)

wherein R^1, R^{2a}, R^{2b}, R^{3a}, R^{3b}, R^4 and R^5 are as defined above for compounds of formula (**I**).

In one embodiment there is provided a compound of formula (**IE**):

The compounds of the disclosure include those where the atom specified is a naturally occurring or non-naturally occurring isotope. In one embodiment the isotope is a stable isotope. Thus the compounds of the disclosure include, for example those containing one or more deuterium atoms in place of hydrogen atoms and the like.

The compounds described herein may include one or more chiral centres, and the disclosure extends to include racemates, both enantiomers (for example each substantially free of the other enantiomer) and all stereoisomers resulting therefrom. In one embodiment one enantiomeric form is present in a purified form that is substantially free of the corresponding entaniomeric form.

The disclosure also extends to all polymorphic forms of the compounds herein defined.

In one aspect a compound of formula (**I**) is:

2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-ethynylquinazolin-4(3*H*)-one;

2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(3-(2-(2-methoxyethoxy)ethoxy)prop-1-yn-1-yl)quinazolin-4(3*H*)-one;

2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;

6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)hex-5-ynoic acid;

2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;

3-((2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-(3-(2-(2-hydroxyethoxy)ethoxy)prop-1-yn-1-yl)-4-oxoquinazolin-3(4*H*)-yl)methyl)benzonitrile;

2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(5-(cyclopentylamino)pent-1-ynyl)quinazolin-4(3*H*)-one;

2-((4-amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl) -5-(3-(2-morpholinoethoxy)prop-1-ynyl)quinazolin-4(3*H*)-one;

2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-ethynylquinazolin-4(3*H*)-one;

2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(3-chloro benzyl)-5-ethynylquinazolin-4(3*H*)-one;

2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-((1-methyl-1*H*-pyrazol-4-yl)methyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;

2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(benzofuran-5-ylmethyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;

2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-((2-methyl thiazol-4-yl)methyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;

2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(6-(4-methylpiperazin-1-yl)-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;

2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(6-(4-morpholinopiperidin-1-yl)-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;

5-(6-(4-Acetylpiperazin-1-yl)-6-oxohex-1-yn-1-yl)-2-((4-amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)quinazolin-4(3*H*)-one;

N-(4-(2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)but-3-yn-1-yl)morpholine-4-carboxamide;

~~5-(6-(4-Acetylpiperazin-1-yl)-6-oxohex-1-yn-1-yl)-2-((4-amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)quinazolin-4(3*H*)-one;~~

~~*N*-(4-(2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)but-3-yn-1-yl)morpholine-4-carboxamide;~~

2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-(5-(bis(2-methoxyethyl)amino)pent-1-ynyl)-3-(2-chlorobenzyl)quinazolin-4(3*H*)-one;

6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-cyclopentylhex-5-ynamide;

6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(tetrahydro-2*H*-pyran-4-yl)hex-5-ynamide;

6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(2-morpholinoethyl)hex-5-ynamide;

2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(6-(4-(2-methoxyethyl)piperazin-1-yl)-6-oxohex-1-ynyl)quinazolin-4(3*H*)-one;

6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(2-(dimethylamino)ethyl)hex-5-ynamide;

6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(pyridin-4-yl)hex-5-ynamide;

6-(2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(pyridin-4-yl)hex-5-ynamide;

2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(6-(4-(dimethylamino)piperidin-1-yl)-6-oxohex-1-ynyl)quinazolin-4(3*H*)-one;

6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*,*N*-bis(2-methoxyethyl)hex-5-ynamide;

~~6-(2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*,*N*-bis(2-methoxyethyl)hex-5-ynamide;~~

6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(2-(4-methylpiperazin-1-yl)ethyl)hex-5-ynamide;

6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-methyl-*N*-(2-(4-methylpiperazin-1-yl)ethyl)hex-5-ynamide;

6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-isopropylhex-5-ynamide;

6-(2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-isopropylhex-5-ynamide;

6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*,*N*-dimethylhex-5-ynamide;

2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(6-oxo-6-(pyrrolidin-1-yl)hex-1-yn-1-yl)quinazolin-4(3*H*)-one;

6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(pyrrolidin-3-yl)hex-5-ynamide;

2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(6-(3-(dimethylamino)pyrrolidin-1-yl)-6-oxohex-1-ynyl)quinazolin-4(3*H*)-one;

The compounds of formulae (**III**), (**VII**), (**VIII**), (**X**) and (**XI**) and (**XII**) as defined above, are either commercially available or can be readily prepared from commericially available starting materials, using routine published techniques (see for example **Table 1**).

A selection of the compounds of formula (**I**), disclosed herein, have been screened by chiral stationary phase HPLC for the presence of non interconverting rotational isomers, otherwise known as atropisomers. Atropisomerism results from hindered rotation about a single bond where the torsional energy barrier to free rotation is sufficiently high to significantly slow the interconversion of non-superimposable conformers. Clayden J. *et al.*, "*The Challenge of Atropisomerism in Drug Discovery*" Angew. Chem. Int. Ed., **2009**, *48*, 6398-6401 highlights the serious barriers to development arising from molecular atropisomerism, which is described in this document as a "lurking menace". LaPlante S.R. *et al.*, "Assessing Atropisomer Axial Chirality in Drug Discovery and Development", J. Med. Chem., **2011**, *54*, 7005-7022 similarly sets out in detail the profound implications of atropisomerism in relation to drug development (see pages 7007-9).The analytical and preparative methods disclosed below have been used to resolve the discrete atropisomers of a number of published PI3K inhibitors, revealing that they ordinarily occur as mixtures of stereoisomers possessing very long half-lives (months or years) under physiological conditions. (See experimental section for details). The occurence of atropisomerism represents an added burden of complexity to the development of such compounds as therapeutic agents, since discrete stereoisomers are usually highly preferred over mixtures, such as racemates. Analysis of selected examples using the chromatographic methods disclosed herein have revealed no evidence that the compounds of formula (**I**) exibit atropisomerism. In the absence of additional features that are well known to give rise to stereoisomers, for example a stereogenic centre, the current disclosure provides for compounds that advantageously exist as single discrete molecular entities. Thus the compounds of the present disclosure are particularly useful as therapeutically active agents in pharmaceutical compositions and in treatment.

In one aspect the compounds are useful in treatment, for example COPD and/or asthma.

The PI3K compounds developed to date have typically been intended for oral administration. Typically this strategy involves the optimisation of a compound's pharmacokinetic profile in order to achieve an adequate duration of action. In this way a sufficiently high drug concentration is established and maintained between doses to provide continuous clinical benefit. An inevitable and frequently undesired consequence of this approach is that non-targeted body tissues, especially the liver and the gut, are likely to be exposed to pharmacologically active concentrations of the drug.

An alternative strategy is to design treatment regimens in which the drug is dosed directly to the inflamed organ (for example topical therapy). Although this approach is not suitable for treating all chronic inflammatory conditions, it has been extensively exploited in treating lung diseases (asthma, COPD), skin lesions (atopic dermatitis and psoriasis), nasal diseases (allergic rhinitis) and gastrointestinal disorders (ulcerative colitis).

In topical therapy, the desired efficacy can sometimes be achieved by ensuring that the drug has a sustained duration of action and is retained predominantly in the target organ, thereby minimising the risks of systemic toxicity. Alternatively an appropriate formulation can be used which generates a "reservoir" of the active drug which is then available to sustain the desired effects. The first approach is exemplified in the use of the anticholinergic drug tiotropium

In one embodiment a compound of formula (I) for the treatment of Hepatitis C is delivered to the blood pre-entry to the liver.

Compounds of the disclosure are also expected to be useful in the treatment of certain other conditions including rheumatoid arthritis, pancreatitis, cachexia, inhibition of the growth and metastasis of tumours including non-small cell lung carcinoma, breast carcinoma, gastric carcinoma, colorectal carcinomas and malignant melanoma.

Thus, in a further aspect, the present invention provides a compound as described herein for use in the treatment of one or more of the above mentioned conditions.

In a further aspect, the present invention provides use of a compound as described herein for the manufacture of a medicament for the treatment of one or more of the above mentioned conditions.

~~In a further aspect, the present invention provides a method of treatment of the above mentioned conditions which comprises administering to a subject an effective amount of a compound of the disclosure or a pharmaceutical composition thereof.~~

Compounds described herein may also be used in the manufacture of a medicament for the treatment of one or more of the above-identified diseases.

The word "treatment" is intended to embrace prophylaxis as well as therapeutic treatment.





A compound of the disclosure may also be administered in combination with one or more other active ingredients e.g. active ingredients suitable for treating the above mentioned conditions. For example possible combinations for treatment of respiratory disorders include combinations with steroids (e.g. budesonide, beclomethasone dipropionate, fluticasone propionate, mometasone furoate, fluticasone furoate), beta agonists (e.g. terbutaline, salbutamol, salmeterol, formoterol, indacaterol) and/or xanthines (e.g. theophylline), musacarinic antagonists, (e.g. ipratropium) and/or a p38 MAP kinase inhibitor.

In one embodiment a compound of the disclosure is administered in combination with an antiviral agent, for example acyclovir, tamiflu, relenza or interferon.

In one embodiment the combination of active ingredients are co-formulated.
In one embodiment the combination of active ingredients is simply co-administered.

EXPERIMENTAL SECTION

Abbreviations

81		2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-(4-(dimethylamino)piperidin-1-yl)-6-oxohex-1-ynyl) quinazolin-4(3*H*)-one. R^t 1.34 min; m/z 730/732 $(M+H)^+$ (ES^+) (Method D); ^{1}H NMR (400 MHz, DMSO) δ: 1.01-1.09 (2H, overlapping m), 1.14-1.24 (3H, overlapping m), 1.61-1.66 (2H, overlapping m), 1.78 (2H, quin), 2.15 (6H, s), 2.17-2.25 (2H, overlapping m), 2.48-2.55 (4H, overlapping m), 5.41 (2H, s), 5.67 (2H, s), 6.27 (2H, br s), 6.48 (1H, d), 6.90-6.97 (3H, overlapping m), 7.12 (1H, m), 7.24 (1H, d), 7.37 (2H, d), 7.54-7.57 (2H, overlapping m), 7.73 (1H, t), 8.17 (1H, s), 9.37 (1H, br s).
82		6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*,*N*-bis(2-methoxyethyl)hex-5-ynamide. R^t 1.89 min; m/z 735/737 $(M+H)^+$ (ES^+) (Method D); ^{1}H NMR (400 MHz, DMSO) δ: 1.70 (2H, quin), 2.45 (2H, t), 2.55 (2H, t), 3.11 (3H, s), 3.18 (3H, s), 3.24-3.35 (8H, overlapping m), 5.28 (2H, s), 5.73 (2H, s), 6.20 (1H, d), 6.79 (1H, t), 6.88 (2H, d), 7.03 (1H, t), 7.13 (1H, d), 7.33 (2H, d), 7.60 (1H, d), 7.67 (1H, d), 7.80 (1H, t), 8.19 (1H, s), 9.75 (1H, s).
~~83~~		~~6-(2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*,*N*-bis(2-methoxyethyl)hex-5-ynamide. R^t 1.92 min; m/z 735/737 $(M+H)^+$ (ES^+) (Method D); ^{1}H NMR (400 MHz, DMSO-d_6) δ: 1.70 (2H, quin), 2.46 (2H, t), 2.55 (2H, t), 3.12 (3H, s), 3.19 (3H, s), 3.26 (2H, overlapping m), 3.31 (4H, m, partially obscured by HOD peak), 3.35 (2H, q), 5.30 (2H, s), 5.76 (2H, s), 6.18 (1H, dd), 6.80 (1H, dt), 6.85 (1H ddd), 6.92-6.94 (2H, overlapping m), 7.05 (1H, td), 7.13 (1H, dd), 7.31 (1H, t), 7.61 (1H, dd), 7.68 (1H, dd), 7.81 (1H, dd), 8.18 (1H, br s), 9.65 (1H, br s).~~
84		6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(2-(4-methylpiperazin-1-yl)ethyl)hex-5-ynamide. R^t 1.34 min; m/z 745/747 $(M+H)^+$ (ES^+) (Method D); ^{1}H VT NMR (400 MHz, 100°C, DMSO-d_6) δ: 1.79 (2H, quin), 2.12 (3H, s), 2.22-2.35 (10H, overlapping m), 2.44-2.50 (4H, overlapping m), 3.12 (2H, q), 5.42 (2H, s), 5.68 (2H, s), 6.28 (2H, s), 6.49 (1H, d), 6.90-6.97 (3H, overlapping m), 7.13 (1H, m), 7.18 (1H, br s), 7.24 (1H, d), 7.37 (2H, d), 7.55-7.58 (2H, overlapping m), 7.74 (1H, t), 8.17 (1H, s), 9.37 (1H, br s).

79	++	+	+	++	-	-
80	++	ND	ND	+	-	-
81	++	+	+	++	-	-
82	++	++	+	++	-	-
83	++	ND	ND	++	-	-
84	++	ND	ND	++	-	-
85	++	ND	ND	++	-	-
86	++	++	++	++	-	-
87	++	ND	ND	++	-	-
88	++	++	+	++	-	-
89	++	++	-	++	-	-
90	++	++	+	++	-	-
91	++	++	+	++	-	-
92	++	ND	ND	+	-	-
93	++	++	+	++	-	-
94	+	ND	ND	+	-	-
95	++	++	+	++	-	-

a) **++** IC_{50} <50 nM, **+** IC_{50} <1000 nM, **-** >1000 nM. **b)** **++** IC_{50} <10 nM; **+** IC_{50} <1000 nM; **c)** **-** <30%; **+** >30%. ND: not done

Table 4: *In Vitro* Screening Data: Kinase Isozyme and Cellular Activity Values for Selected Exemplified Compounds

Test Cmpd	**PI3 Kinase Inhibition** IC_{50} values at stated Isozyme (nM)			**Cellular Activity** IC_{50} values (H_2O_2 induced pAkt (nM)
Example	***δ***	**γ**	***α***	D-U937 Cells
1	7	234	199	1.1
4	12	20	17	1.8

fluticasone propionate, at a dose which lacks effect as monotherapy, a marked enhancement of anti-inflammatory activtiy was detected. Data for cell numbers are shown as the mean ± SEM.


Throughout the specification and the claims which follow, unless the context requires otherwise, the word 'comprise', and variations such as 'comprises' and 'comprising', will be understood to imply the inclusion of a stated integer, step, group of integers or group of steps but not to the exclusion of any other integer, step, group of integers or group of steps.

~~All patents and patent applications referred to herein are incorporated by reference in their entirety.~~

The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process, or use claims and may include, by way of example and without limitation, the claims.

Claims

1. A compound of formula (I)



(I)

wherein

R^1 is H, a saturated or unsaturated, branched or unbranched C_{1-15} alkyl chain, wherein optionally one or more carbons (for example 1, 2 or 3 carbons, suitably 1 or 2, in particular 1) is/are replaced by a heteroatom selected from O, N, $S(O)_p$, (for example a CH_2, group is replaced with O, or with NH, or with S, or with SO_2 or a $-CH_3$ group at the terminus of the chain or on a branch is replaced with OH or with NH_2) wherein said chain is optionally substituted by one or more groups (for example 1 to 3, such as 2 groups) independently selected from oxo, halogen, an aryl group, a heteroaryl group, a carbocyclyl group or a heterocyclyl group,

each aryl, heteroaryl, carbocyclyl or heterocyclyl group bearing:

0 to 3 substituents selected from halogen, -hydroxyl, $-C_{1-6}$ alkyl, $-C_{1-6}$ alkoxy, $-C_{2-3}$ alkoxyOC_{1-3} alkyl, $-C_{2-3}$ alkylOC_{1-3} alkyl, $-C_{1-3}$ hydroxyalkyl, $-C_{1-6}$ haloalkyl, amino, $-C_{1-4}$ mono or $-C_{2-8}$ di-alkyl amino, $-C_{1-4}$ mono or $-C_{2-8}$ di-acyl amino, $-C_{0-6}$ alkyl$S(O)_pC_{1-6}$ alkyl, $-C_{0-6}$ alkyl$S(O)_pNR^6R^7$, $-C_{0-6}$ alkylNR^8C_{0-6}alkyl$S(O)_pC_{1-6}$ alkyl, $-C_{0-6}$ alkyl$C(O)OC_{0-6}$ alkyl, $-NR^8C_{0-6}$ alkyl$C(O)NR^6R^7$ $-NR^8C_{0-6}$ alkyl$C(O)C_{0-6}$ alkyl, $-C_{0-6}$ alkyl$C(O)NR^6R^7$, and $-C_{0-6}$ alkyl$C(O)C_{1-6}$ alkyl; and/or one aryl, heterocyclyl or carbocyclyl;

X is C_{6-10} aryl or a C_{5-9} heteroaryl each substituted by R^{2a} and by R^{2b}

wherein R^{2a} is selected from hydrogen, $-C_{1-3}$ alkyl, halo, hydroxyl, cyano, $-C_{1-3}$ haloalkyl, $-C_{1-3}$ alkoxy, $-C_{2-3}$ alkoxyOC_{1-3} alkyl, $-C_{2-3}$ alkylOC_{1-3} alkyl, $-C_{1-3}$ hydroxyalkyl, $-C_{0-6}$ alkyl$S(O)_qC_{1-3}$ alkyl, $-C_{0-6}$ alkyl$S(O)_pNR^6R^7$, $-C_{0-6}$ alkylNR^8C_{0-6}alkyl$S(O)_pC_{1-6}$ alkyl, $-C_{0-6}$ alkyl$C(O)OH$, $-C_{0-6}$ alkyl$C(O)OC_{1-6}$ alkyl, $-NR^8C_{0-6}$ alkyl$C(O)NR^6R^7$, $-NR^8C_{0-6}$ alkyl$C(O)C_{1-6}$ alkyl, $-C_{0-6}$ alkyl$C(O)NR^6R^7$ and $-C_{0-6}$ alkyl$C(O)C_{1-6}$ alkyl; and

R^{2b} is selected from hydrogen, C_{1-3} alkyl, halo, hydroxyl, cyano, $-C_{1-3}$ haloalkyl, $-C_{1-3}$ alkoxy, and $-C_{0-6}$ alkyl$S(O)_qC_{1-3}$ alkyl;

R^{3a} is hydroxyl;

R^{3b} is selected from hydrogen, hydroxyl, halo, cyano, $-C_{1-3}$ haloalkyl, $-C_{1-3}$

hydroxyalkyl, -C_{1-3} alkoxy, and -$S(O)_qC_{1-3}$ alkyl;

R^4 is hydrogen or -C_{1-3} alkyl;

R^5 is hydrogen or -C_{1-3} alkyl;

R^6 is hydrogen or -C_{1-6} alkyl;

R^7 is hydrogen or -C_{1-6} alkyl;

R^8 is hydrogen or -C_{1-6} alkyl;

p is 0 or an integer 1 or 2;

q is 0 or an integer 1 or 2

or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof.

2. A compound of formula (I) according to claim 1 wherein:

R^1 is H, a saturated or unsaturated, branched or unbranched C_{1-10} alkyl chain, wherein optionally one or more carbons (for example 1, 2 or 3 carbons, suitably 1 or 2, in particular 1) is/are replaced by a heteroatom selected from O, N, $S(O)_p$, (for example a CH_2, group is replaced with O, or with NH, or with S, or with SO_2 or a $-CH_3$ group at the terminus of the chain or on a branch is replaced with OH or with NH_2) wherein said chain is optionally substituted by one or more groups (for example 1 to 3, such as 2 groups) independently selected from oxo, halogen, an aryl group, a heteroaryl group, a carbocyclyl group or a heterocyclyl group,

each aryl, heteroaryl, carbocyclyl or heterocyclyl group bearing:

0 to 3 substituents selected from halogen, -C_{1-6} alkyl, -C_{1-6} alkoxy, -C_{2-3} alkoxyOC_{1-3} alkyl, -C_{1-6} haloalkyl, amino, -C_{1-4} mono or -C_{2-8} di-alkyl amino, -C_{1-4} mono or -C_{2-8} di-acyl amino, -C_{0-6} alkyl$S(O)_pC_{1-6}$ alkyl, -C_{0-6} alkyl$S(O)_pNR^6R^7$, -C_{0-6} alkylNR^8C_{0-6}alkyl$S(O)_pC_{1-6}$ alkyl, -C_{0-6} alkyl$C(O)OC_{0-6}$ alkyl, -NC_{0-6} alkyl$C(O)NR^6R^7$ -NC_{0-6} alkyl$C(O)C_{0-6}$ alkyl, -C_{0-6} alkyl$C(O)NR^6R^7$, and -C_{0-6} alkyl$C(O)C_{1-6}$ alkyl; and/or one aryl, heterocyclyl or carbocyclyl;

X is C_{6-10} aryl or a C_{5-9} heteroaryl each substituted by R^{2a} and optionally by R^{2b} wherein R^{2a} is selected from hydrogen, -C_{1-3} alkyl, halo, hydroxyl, cyano, -C_{1-3} haloalkyl, -C_{1-3} alkoxy, -C_{2-3} alkoxyOC_{1-3} alkyl, -C_{1-3} hydroxyalkyl, -C_{0-6} alkyl$S(O)_qC_{1-3}$ alkyl, -C_{0-6} alkyl$S(O)_pNR^6R^7$, -C_{0-6} alkylNR^6C_{0-6}alkyl$S(O)_pC_{1-6}$ alkyl, -C_{0-6} alkyl$C(O)OH$, -C_{0-6} alkyl$C(O)OC_{1-6}$ alkyl, -NC_{0-6} alkyl$C(O)NR^6R^7$, -NR^8C_{0-6} alkyl$C(O)C_{1-6}$ alkyl, -C_{0-6} alkyl$C(O)NR^6R^7$ and -C_{0-6} alkyl$C(O)C_{1-6}$ alkyl; and

R^{2b} is selected from hydrogen, C_{1-3} alkyl, halo, cyano, -C_{1-3} haloalkyl, -C_{1-3} alkoxy and -C_{0-6} alkyl$S(O)_qC_{1-3}$ alkyl;

R^{3a} is hydroxyl;

R^{3b} is hydrogen, hydroxyl, halo, cyano, -C_{1-3} haloalkyl, -C_{1-3} hydroxyalkyl, -C_{1-3} alkoxy, -$S(O)_qC_{1-3}$ alkyl;


R^4 is hydrogen or -C_{1-3} alkyl;

R^5 is hydrogen or -C_{1-3} alkyl;

R^6 is hydrogen or -C_{1-6} alkyl;

R^7 is hydrogen or -C_{1-6} alkyl;
R^8 is hydrogen or -C_{1-6} alkyl
p is 0 or an integer 1 or 2;
q is 0 or an integer 1 or 2
or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof.

3. A compound of formula (I) according to claim 1 or 2, wherein R^1 is hydrogen.
4. A compound of formula (I) according to claim 1 or 2 wherein R^1 is:



5. A compound of formula (I) according to claim 1 or 2 wherein R^1 is $-CH_2CH_2CH_2C(O)OH$.
6. A compound of formula (I) according to claim 1 or 2 wherein R^1 is $-CH_2OCH_2CH_2OCH_2CH_2OCH_3$.
7. A compound of formula (I) according to any one of claims 1 to 6, wherein R^{2a} is selected from the group comprising chloro, fluoro, cyano, methoxy, trifluoromethyl and SO_2CH_3.
8. A compound of formula (I) according to any one of claims 1 to 7, wherein R^4 is hydrogen.
9 A compound of formula (I) according to any one of claims 1 to 8, wherein R^5 is hydrogen.
10 A compound of formula (I) according to any one of claims 1 to 9, wherein R^3 is in the *meta* position.
11. A compound of formula (I) according to any one of claims 1 to 9, wherein R^3 is in the *para* position.
12. A compound of formula (I) according to any one of claims 1 to 11, wherein carbocyclyl is a C_{3-10} saturated or partially saturated carbocyclic ring systems, for example cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
13. A compound of formula (I) according to any one of claims 1 to 12, wherein heteroaryl is a C_{5-9} membered aromatic carbocylic ring or bicyclic ring system comprising one or more, (for example 1, 2, 3 or 4) heteroatoms independently selected from O, N and S.
14. A compound of formula (I) according to any one of claims 1 to 13, wherein heterocyclic is intended to refer to a 5 to 10 membered ring system which is saturated or partially unsaturated and which is non-aromatic comprising one or more (for example 1, 2 or 3 in particular 1 or 2,) heteroatoms independently selected from O, N and S,
15. A compound of formula (I) according to any one of claims 1 to 13, wherein aryl is C_{6-14} mono or polycyclic groups (such as C_{6-10} mono or bicyclic groups) having from 1 to 3 rings wherein at least one ring is aromatic.
16. A compound of formula (I) according to claim 1, wherein the compound is selected from:
2-((4-Amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-ethynylquinazolin-4(3H)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(3-(2-(2-methoxyethoxy)ethoxy)prop-1-yn-1-yl)quinazolin-4(3H)-one;

2-((4-Amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3H)-one;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)hex-5-ynoic acid;
2-((4-Amino-3-(4-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3H)-one;
3-((2-((4-Amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-(3-(2-(2-hydroxyethoxy)ethoxy)prop-1-yn-1-yl)-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(3-(2-morpholinoethoxy)prop-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(3-chloro benzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(3-chloro benzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(2-fluorobenzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(2-fluorobenzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(3-methoxybenzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(3-methoxybenzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(3-(trifluoromethyl)benzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(3-(trifluoromethyl)benzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(4-chlorobenzyl)-5-ethynyl quinazolin-4(3*H*)-one.;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(4-(methylsulfonyl)benzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(4-(methylsulfonyl)benzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(4-(trifluoromethyl)benzyl)quinazolin-4(3*H*)-one;
3-((2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-4-oxoquinazolin-3(4*H*)-yl)methyl)benzonitrile;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(3-(methylsulfonyl)benzyl)quinazolin-4(3*H*)-one;
3-((2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-4-oxoquinazolin-3(4*H*)-yl)methyl)benzonitrile;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(4-chloro

benzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(4-chloro benzyl)-5-(3-methoxyprop-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(3-methoxy benzyl)-5-(3-methoxyprop-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(3-methoxyprop-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(4-(trifluoromethyl)benzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(3-(2-methoxyethoxy)prop-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-((5-methylisoxazol-3-yl)methyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-((5-methylisoxazol-3-yl)methyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(3-chloro-2-fluorobenzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2,6-difluorobenzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(4-chloro-2-fluorobenzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-fluoro-4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-(3-methoxy prop-1-ynyl)-3-(3-(trifluoromethyl)benzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(4-fluorobenzyl) quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(3-cyclopentylprop-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-(3-(benzyloxy)prop-1-ynyl)-3-(2-chlorobenzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(5-hydroxypent-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(2-fluoro-5-methoxybenzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(3,4-dichlorobenzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-benzyl-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(2-trifluoromethylbenzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(4-methoxybenzyl)quinazolin-4(3*H*)-one;

4-((2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-4-oxoquinazolin-3(4*H*)-yl)methyl)benzonitrile;

2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(2-fluoro-4-methoxybenzyl)quinazolin-4(3*H*)-one;

1-(3-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)prop-2-ynyl)urea;

2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-fluorobenzyl)-5-(3-(2-(2-methoxyethoxy)ethoxy)prop-1-ynyl)quinazolin-4(3*H*)-one;

2-((4-Amino-3-(4-fluoro-3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-ethynylquinazolin-4(3*H*)-one;

2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(3-phenoxyprop-1-ynyl)quinazolin-4(3*H*)-one;

2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-fluoro benzyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;

6-(2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(2-methoxyethyl)hex-5-ynamide;

2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(7-morpholino-7-oxohept-1-yn-1-yl)quinazolin-4(3*H*)-one;

2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(5-morpholino-5-oxopent-1-yn-1-yl)quinazolin-4(3*H*)-one;

2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-((5-methyl pyrazin-2-yl)methyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;

2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(6-oxo-6-(piperidin-1-yl)hex-1-yn-1-yl)quinazolin-4(3*H*)-one;

6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N,N*-diethylhex-5-ynamide;

7-(2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)hept-6-ynoic acid;

2-Acetamido-N-(3-(2-((4-amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl) methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)prop-2-yn-1-yl)acetamide;

2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(3-methoxy-5-(trifluoromethyl)benzyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;

2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-methoxy phenethyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;

2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(benzo[*b*]thiophen-2-ylmethyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;

2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-fluoro-3-methoxybenzyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;

Methyl 3-((2-((4-amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)-4-oxoquinazolin-3(4*H*)-yl)methyl)benzoate;

2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-((1-methyl-1*H*-pyrazol-4-yl)methyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;

2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(benzofuran-5-ylmethyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-((2-methyl thiazol-4-yl)methyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(6-(4-methylpiperazin-1-yl)-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(6-(4-morpholinopiperidin-1-yl)-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;
5-(6-(4-Acetylpiperazin-1-yl)-6-oxohex-1-yn-1-yl)-2-((4-amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)quinazolin-4(3*H*)-one;
N-(4-(2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)but-3-yn-1-yl)morpholine-4-carboxamide;
5-(6-(4-Acetylpiperazin-1-yl)-6-oxohex-1-yn-1-yl)-2-((4-amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)quinazolin-4(3*H*)-one;
N-(4-(2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)but-3-yn-1-yl)morpholine-4-carboxamide;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-(5-(bis(2-methoxyethyl)amino)pent-1-ynyl)-3-(2-chlorobenzyl)quinazolin-4(3*H*)-one;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-cyclopentylhex-5-ynamide;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(tetrahydro-2*H*-pyran-4-yl) hex-5-ynamide;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(2-morpholinoethyl)hex-5-ynamide;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-(4-(2-methoxyethyl)piperazin-1-yl)-6-oxohex-1-ynyl) quinazolin-4(3*H*)-one;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(2-(dimethylamino)ethyl) hex-5-ynamide;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(pyridin-4-yl)hex-5-ynamide;
6-(2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(pyridin-4-yl)hex-5-ynamide;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-(4-(dimethylamino)piperidin-1-yl)-6-oxohex-1-ynyl) quinazolin-4(3*H*)-one;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*,*N*-bis(2-methoxyethyl)hex-5-ynamide;
6-(2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*,*N*-bis(2-methoxyethyl)hex-5-ynamide;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-


chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(2-(4-methylpiperazin-1-yl)ethyl)hex-5-ynamide;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-methyl-*N*-(2-(4-methyl piperazin-1-yl)ethyl)hex-5-ynamide;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-isopropylhex-5-ynamide;
6-(2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-isopropylhex-5-ynamide;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*,*N*-dimethylhex-5-ynamide;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-oxo-6-(pyrrolidin-1-yl)hex-1-yn-1-yl)quinazolin-4(3*H*)-one;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(pyrrolidin-3-yl)hex-5-ynamide;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-(3-(dimethylamino)pyrrolidin-1-yl)-6-oxohex-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-(3-(dimethylamino)pyrrolidin-1-yl)-6-oxohex-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-(4-methyl-1,4-diazepan-1-yl)-6-oxohex-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-(4-methyl-1,4-diazepan-1-yl)-6-oxohex-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxy-3-methoxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-morpholino-6-oxohex-1-ynyl)quinazolin-4(3*H*)-one;
or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof.

17. A pharmaceutical composition comprising a compound according to any one of claims 1 to 16, in combination with one or more pharmaceutically acceptable diluents or carriers.
18. A compound of formula (I) according to any one of claims 1 to 16 for use as a medicament.
19. A compound of formula (I) according to any one of claims 1 to 16 for use as in the treatment or prevention of a condition selected from:
COPD (including chronic bronchitis and emphysema), asthma, paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, allergic rhinitis, rhinitis, sinusitis, allergic conjunctivitis, conjunctivitis, allergic dermatitis, contact dermatitis, psoriasis, ulcerative colitis, inflamed joints secondary to rheumatoid arthritis or osteoarthritis, rheumatoid arthritis, pancreatitis, cachexia, inhibition of the growth and metastasis of tumours including non-small cell lung carcinoma, breast carcinoma, gastric carcinoma, colorectal carcinomas and malignant melanoma.
20. Use of a compound of formula (I) according to any one of claims 1 to 16 for the

manufacture of a medicament for the treatment or prevention of a condition selected from
COPD (including chronic bronchitis and emphysema), asthma, paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, allergic rhinitis, rhinitis, sinusitis, allergic conjunctivitis, conjunctivitis, allergic dermatitis, contact dermatitis, psoriasis, ulcerative colitis, inflamed joints secondary to rheumatoid arthritis or osteoarthritis, rheumatoid arthritis, pancreatitis, cachexia, inhibition of the growth and metastasis of tumours including non-small cell lung carcinoma, breast carcinoma, gastric carcinoma, colorectal carcinomas and malignant melanoma.

21. A method of treatment of a condition selected from
COPD (including chronic bronchitis and emphysema), asthma, paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, allergic rhinitis, rhinitis, sinusitis, allergic conjunctivitis, conjunctivitis, allergic dermatitis, contact dermatitis, psoriasis, ulcerative colitis, inflamed joints secondary to rheumatoid arthritis or osteoarthritis, rheumatoid arthritis, pancreatitis, cachexia, inhibition of the growth and metastasis of tumours including non-small cell lung carcinoma, breast carcinoma, gastric carcinoma, colorectal carcinomas and malignant melanoma
which comprises administering to a subject an effective amount of a compound of formula (I) according to any one of claims 1 to 16 or a pharmaceutical composition according to claim 17.


22. An intermediate of formula (VI):



(VI)

wherein LG_1 and LG_3 independently represent a leaving group and X, R^4 and R^5 are as defined in claim 1.

23. An intermediate of formula (II):




(II)

wherein LG_1 represents a leaving group and X, R^{3a}, R^{3b}, R^4 and R^5 are as defined in claim 1.

24. An intermediate according to claim 22 or claim 23, wherein LG_1 is bromine.

Claims

1. A compound of formula (I)



(I)

wherein

R^1 is H, a saturated or unsaturated, branched or unbranched C_{1-15} alkyl chain, wherein optionally one or more carbons is/are replaced by a heteroatom selected from O, N, $S(O)_p$, wherein said chain is optionally substituted by one or more groups independently selected from oxo, halogen, an aryl group, a heteroaryl group, a carbocyclyl group or a heterocyclyl group,

each aryl, heteroaryl, carbocyclyl or heterocyclyl group bearing:

0 to 3 substituents selected from halogen, -hydroxyl, $-C_{1-6}$ alkyl, $-C_{1-6}$ alkoxy, $-C_{2-3}$ alkoxyOC_{1-3} alkyl, $-C_{2-3}$ alkylOC_{1-3} alkyl, $-C_{1-3}$ hydroxyalkyl, $-C_{1-6}$ haloalkyl, amino, $-C_{1-4}$ mono or $-C_{2-8}$ di-alkyl amino, $-C_{1-4}$ mono or $-C_{2-8}$ di-acyl amino, $-C_{0-6}$ alkyl$S(O)_pC_{1-6}$ alkyl, $-C_{0-6}$ alkyl$S(O)_pNR^6R^7$, $-C_{0-6}$ alkylNR^8C_{0-6}alkyl$S(O)_pC_{1-6}$ alkyl, $-C_{0-6}$ alkyl$C(O)OC_{0-6}$ alkyl, $-NR^8C_{0-6}$ alkyl$C(O)NR^6R^7$ $-NR^8C_{0-6}$ alkyl$C(O)C_{0-6}$ alkyl, $-C_{0-6}$ alkyl$C(O)NR^6R^7$, and $-C_{0-6}$ alkyl$C(O)C_{1-6}$ alkyl; and/or one aryl, heterocyclyl or carbocyclyl;

X is C_{6-10} aryl or a C_{5-9} heteroaryl each substituted by R^{2a} and by R^{2b}

wherein R^{2a} is selected from hydrogen, $-C_{1-3}$ alkyl, halo, hydroxyl, cyano, $-C_{1-3}$ haloalkyl, $-C_{1-3}$ alkoxy, $-C_{2-3}$ alkoxyOC_{1-3} alkyl, $-C_{2-3}$ alkylOC_{1-3} alkyl, $-C_{1-3}$ hydroxyalkyl, $-C_{0-6}$ alkyl$S(O)_qC_{1-3}$ alkyl, $-C_{0-6}$ alkyl$S(O)_pNR^6R^7$, $-C_{0-6}$ alkylNR^8C_{0-6}alkyl$S(O)_pC_{1-6}$ alkyl, $-C_{0-6}$ alkyl$C(O)OH$, $-C_{0-6}$ alkyl$C(O)OC_{1-6}$ alkyl, $-NR^8C_{0-6}$ alkyl$C(O)NR^6R^7$, $-NR^8C_{0-6}$ alkyl$C(O)C_{1-6}$ alkyl, $-C_{0-6}$ alkyl$C(O)NR^6R^7$ and $-C_{0-6}$ alkyl$C(O)C_{1-6}$ alkyl; and

R^{2b} is selected from hydrogen, C_{1-3} alkyl, halo, hydroxyl, cyano, $-C_{1-3}$ haloalkyl, $-C_{1-3}$ alkoxy, and $-C_{0-6}$ alkyl$S(O)_qC_{1-3}$ alkyl;

R^{3a} is hydroxyl;

R^{3b} is selected from hydrogen, hydroxyl, halo, cyano, $-C_{1-3}$ haloalkyl, $-C_{1-3}$ hydroxyalkyl, $-C_{1-3}$ alkoxy, and $-S(O)_qC_{1-3}$ alkyl;

R^4 is hydrogen or $-C_{1-3}$ alkyl;

R^5 is hydrogen or $-C_{1-3}$ alkyl;

R^6 is hydrogen or $-C_{1-6}$ alkyl;

R^7 is hydrogen or -C_{1-6} alkyl;
R^8 is hydrogen or -C_{1-6} alkyl;
p is 0 or an integer 1 or 2;
q is 0 or an integer 1 or 2;
provided that the compound of formula (I) is not 6-(2-((4-amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*,*N*-bis(2-methoxyethyl)hex-5-ynamide;
or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof.

2. A compound of formula (I) according to claim 1 wherein:
R^1 is H, a saturated or unsaturated, branched or unbranched C_{1-10} alkyl chain, wherein optionally one or more carbons is/are replaced by a heteroatom selected from O, N, $S(O)_p$, wherein said chain is optionally substituted by one or more groups independently selected from oxo, halogen, an aryl group, a heteroaryl group, a carbocyclyl group or a heterocyclyl group,
each aryl, heteroaryl, carbocyclyl or heterocyclyl group bearing:
0 to 3 substituents selected from halogen, -C_{1-6} alkyl, -C_{1-6} alkoxy, -C_{2-3} alkoxyOC_{1-3} alkyl, -C_{1-6} haloalkyl, amino, -C_{1-4} mono or -C_{2-8} di-alkyl amino, -C_{1-4} mono or -C_{2-8} di-acyl amino, -C_{0-6} alkyl$S(O)_pC_{1-6}$ alkyl, -C_{0-6} alkyl$S(O)_pNR^6R^7$, -C_{0-6} alkylNR^8C_{0-6}alkyl$S(O)_pC_{1-6}$ alkyl, -C_{0-6} alkyl$C(O)OC_{0-6}$ alkyl, -NC_{0-6} alkyl$C(O)NR^6R^7$ -NC_{0-6} alkyl$C(O)C_{0-6}$ alkyl, -C_{0-6} alkyl$C(O)NR^6R^7$, and -C_{0-6} alkyl$C(O)C_{1-6}$ alkyl; and/or one aryl, heterocyclyl or carbocyclyl;
X is C_{6-10} aryl or a C_{5-9} heteroaryl each substituted by R^{2a} and optionally by R^{2b}
wherein R^{2a} is selected from hydrogen, -C_{1-3} alkyl, halo, hydroxyl, cyano, -C_{1-3} haloalkyl, -C_{1-3} alkoxy, -C_{2-3} alkoxyOC_{1-3} alkyl, -C_{1-3} hydroxyalkyl, -C_{0-6} alkyl$S(O)_qC_{1-3}$ alkyl, -C_{0-6} alkyl$S(O)_pNR^6R^7$, -C_{0-6} alkylNR^8C_{0-6}alkyl$S(O)_pC_{1-6}$ alkyl, -C_{0-6} alkyl$C(O)OH$, -C_{0-6} alkyl$C(O)OC_{1-6}$ alkyl, -NC_{0-6} alkyl$C(O)NR^6R^7$, -NR^8C_{0-6} alkyl$C(O)C_{1-6}$ alkyl, -C_{0-6} alkyl$C(O)NR^6R^7$ and -C_{0-6} alkyl$C(O)C_{1-6}$ alkyl; and
R^{2b} is selected from hydrogen, C_{1-3} alkyl, halo, cyano, -C_{1-3} haloalkyl, -C_{1-3} alkoxy and -C_{0-6} alkyl$S(O)_qC_{1-3}$ alkyl;
R^{3a} is hydroxyl;
R^{3b} is hydrogen, hydroxyl, halo, cyano, -C_{1-3} haloalkyl, -C_{1-3} hydroxyalkyl, -C_{1-3} alkoxy, -$S(O)_qC_{1-3}$ alkyl;
R^4 is hydrogen or -C_{1-3} alkyl;
R^5 is hydrogen or -C_{1-3} alkyl;
R^6 is hydrogen or -C_{1-6} alkyl;
R^7 is hydrogen or -C_{1-6} alkyl;
R^8 is hydrogen or -C_{1-6} alkyl
p is 0 or an integer 1 or 2;
q is 0 or an integer 1 or 2

or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof.

3. A compound of formula (I) according to claim 1 or 2 wherein R^1 is $-CH_2CH_2CH_2C(O)N(CH_2CH_2OCH_3)_2$.

4. A compound of formula (I) according to claim 1 or 2 wherein R^1 is $-CH_2OCH_2CH_2OCH_2CH_2OCH_3$.

5. A compound of formula (I) according to any one of claims 1 to 4, wherein R^{2a} is selected from the group comprising chloro, fluoro, cyano, methoxy, trifluoromethyl and SO_2CH_3.

6. A compound of formula (I) according to any one of claims 1 to 5, wherein R^{2a} is located in the ortho position.

7. A compound of formula (I) according to any one of claims 1 to 6, wherein R^4 is hydrogen.

8 A compound of formula (I) according to any one of claims 1 to 7, wherein R^5 is hydrogen.

9 A compound of formula (I) according to any one of claims 1 to 8, wherein R^{3a} is in the *meta* position.

10. A compound of formula (I) according to any one of claims 1 to 9, wherein carbocyclyl is a C_{3-10} saturated or partially saturated carbocyclic ring system; and
wherein heteroaryl is a C_{5-9} membered aromatic carbocylic ring or bicyclic ring system comprising one or more heteroatoms independently selected from O, N and S; and
wherein heterocyclic is intended to refer to a 5 to 10 membered ring system which is saturated or partially unsaturated and which is non-aromatic comprising one or more heteroatoms independently selected from O, N and S; and
wherein aryl is C_{6-14} mono or polycyclic groups having from 1 to 3 rings wherein at least one ring is aromatic.

11. A compound of formula (I) according to claim 1, wherein the compound is selected from:
2-((4-Amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-ethynylquinazolin-4(3H)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(3-(2-(2-methoxyethoxy)ethoxy)prop-1-yn-1-yl)quinazolin-4(3H)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3H)-one;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)hex-5-ynoic acid;

2-((4-Amino-3-(4-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3H)-one;
3-((2-((4-Amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-(3-(2-(2-hydroxyethoxy)ethoxy)prop-1-yn-1-yl)-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(5-(cyclopentylamino)pent-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(3-(2-morpholinoethoxy)prop-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(3-chloro benzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(3-chloro benzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(2-fluorobenzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(2-fluorobenzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(3-methoxybenzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(3-methoxybenzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(3-(trifluoromethyl)benzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(3-(trifluoromethyl)benzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(4-chlorobenzyl)-5-ethynyl quinazolin-4(3*H*)-one.;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(4-(methylsulfonyl)benzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(4-(methylsulfonyl)benzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(4-(trifluoromethyl)benzyl)quinazolin-4(3*H*)-one;
3-((2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-4-oxoquinazolin-3(4*H*)-yl)methyl)benzonitrile;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(3-(methylsulfonyl)benzyl)quinazolin-4(3*H*)-one;
3-((2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-4-oxoquinazolin-3(4*H*)-yl)methyl)benzonitrile;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(4-chloro benzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(4-chloro

benzyl)-5-(3-methoxyprop-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(3-methoxy benzyl)-5-(3-methoxyprop-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(3-methoxyprop-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(4-(trifluoromethyl)benzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(3-(2-methoxyethoxy)prop-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-((5-methylisoxazol-3-yl)methyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-((5-methylisoxazol-3-yl)methyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(3-chloro-2-fluorobenzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2,6-difluorobenzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(4-chloro-2-fluorobenzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-fluoro-4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-(3-methoxy prop-1-ynyl)-3-(3-(trifluoromethyl)benzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(4-fluorobenzyl) quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(3-cyclopentylprop-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-(3-(benzyloxy)prop-1-ynyl)-3-(2-chlorobenzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(5-hydroxypent-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(2-fluoro-5-methoxybenzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(3,4-dichlorobenzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-benzyl-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(2-trifluoromethylbenzyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(4-methoxybenzyl)quinazolin-4(3*H*)-one;
4-((2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-4-oxoquinazolin-3(4*H*)-yl)methyl)benzonitrile;

2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-ethynyl-3-(2-fluoro-4-methoxybenzyl)quinazolin-4(3*H*)-one;
1-(3-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)prop-2-ynyl)urea;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-fluorobenzyl)-5-(3-(2-(2-methoxyethoxy)ethoxy)prop-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-fluoro-3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-ethynylquinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(3-phenoxyprop-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-fluoro benzyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;
6-(2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(2-methoxyethyl)hex-5-ynamide;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(7-morpholino-7-oxohept-1-yn-1-yl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(5-morpholino-5-oxopent-1-yn-1-yl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-((5-methyl pyrazin-2-yl)methyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(6-oxo-6-(piperidin-1-yl)hex-1-yn-1-yl)quinazolin-4(3*H*)-one;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N,N*-diethylhex-5-ynamide;
7-(2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)hept-6-ynoic acid;
2-Acetamido-N-(3-(2-((4-amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl) methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)prop-2-yn-1-yl)acetamide;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(3-methoxy -5-(trifluoromethyl)benzyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-methoxyphenethyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(benzo[*b*]thiophen-2-ylmethyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-fluoro-3-methoxybenzyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;
Methyl 3-((2-((4-amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)-4-oxoquinazolin-3(4*H*)-yl)methyl)benzoate;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-((1-methyl-1*H*-pyrazol-4-yl)methyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(benzofuran-5-ylmethyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;

2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-((2-methyl thiazol-4-yl)methyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(6-(4-methylpiperazin-1-yl)-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chloro benzyl)-5-(6-(4-morpholinopiperidin-1-yl)-6-oxohex-1-yn-1-yl)quinazolin-4(3*H*)-one;
5-(6-(4-Acetylpiperazin-1-yl)-6-oxohex-1-yn-1-yl)-2-((4-amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)quinazolin-4(3*H*)-one;
N-(4-(2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)but-3-yn-1-yl)morpholine-4-carboxamide;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-5-(5-(bis(2-methoxyethyl)amino)pent-1-ynyl)-3-(2-chlorobenzyl)quinazolin-4(3*H*)-one;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-cyclopentylhex-5-ynamide;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(tetrahydro-2*H*-pyran-4-yl) hex-5-ynamide;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(2-morpholinoethyl)hex-5-ynamide;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-(4-(2-methoxyethyl)piperazin-1-yl)-6-oxohex-1-ynyl)quinazolin-4(3*H*)-one;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(2-(dimethylamino)ethyl) hex-5-ynamide;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(pyridin-4-yl)hex-5-ynamide;
6-(2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(pyridin-4-yl)hex-5-ynamide;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-(4-(dimethylamino)piperidin-1-yl)-6-oxohex-1-ynyl) quinazolin-4(3*H*)-one;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*,*N*-bis(2-methoxyethyl)hex-5-ynamide;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(2-(4-methylpiperazin-1-yl)ethyl)hex-5-ynamide;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-methyl-*N*-(2-(4-methyl piperazin-1-yl)ethyl)hex-5-ynamide;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-isopropylhex-5-ynamide;
6-(2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-

chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-isopropylhex-5-ynamide;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*,*N*-dimethylhex-5-ynamide;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-oxo-6-(pyrrolidin-1-yl)hex-1-yn-1-yl)quinazolin-4(3*H*)-one;
6-(2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N*-(pyrrolidin-3-yl)hex-5-ynamide;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-(3-(dimethylamino)pyrrolidin-1-yl)-6-oxohex-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-(3-(dimethylamino)pyrrolidin-1-yl)-6-oxohex-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-(4-methyl-1,4-diazepan-1-yl)-6-oxohex-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-(4-methyl-1,4-diazepan-1-yl)-6-oxohex-1-ynyl)quinazolin-4(3*H*)-one;
2-((4-Amino-3-(4-hydroxy-3-methoxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-5-(6-morpholino-6-oxohex-1-ynyl)quinazolin-4(3*H*)-one;
or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof.

12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11, in combination with one or more pharmaceutically acceptable diluents or carriers.

13. A compound of formula (I) according to any one of claims 1 to 11 for use as a medicament.

14. A compound of formula (I) according to any one of claims 1 to 11 for use as in the treatment or prevention of a condition selected from:
COPD, asthma, paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, allergic rhinitis, rhinitis, sinusitis,
allergic conjunctivitis, conjunctivitis, allergic dermatitis, contact dermatitis, psoriasis, ulcerative colitis, inflamed joints secondary to rheumatoid arthritis or osteoarthritis,
rheumatoid arthritis, pancreatitis, cachexia, inhibition of the growth and metastasis of tumours including non-small cell lung carcinoma, breast carcinoma, gastric carcinoma, colorectal carcinomas and malignant melanoma.


15. A compound for use according to claim 13 in combination with one or more other active ingredients.

16. A compound according to any one of claims 1 to 11 for use in the treatment of a respiratory disorder in combination with one or more other active ingredients selected

from:
steroids;
beta agonists, ;xanthines;
muscarinic antagonists; and
p38 MAP kinase inhibitors;
or a compound according to any one of claims 1 to 11 for use in combination with an antiviral agent.

17. A compound for use according to claim 16 wherein the one or more other active ingredients are selected from budesonide, beclomethasone dipropionate, fluticasone propionate, mometasone furoate, fluticasone furoate, terbutaline, salbutamol, salmeterol, formoterol, indacaterol, theophylline and ipratropium.


18. An intermediate of formula (VI) :



(VI)

wherein LG_1 and LG_3 independently represent halo; and
X, R^4 and R^5 are as defined in claim 1.

19. An intermediate of formula (II):



(II)

wherein LG_1 represents halo; and
X, R^{3a}, R^{3b}, R^4 and R^5 are as defined in claim 1.